AstraZeneca to Establish $2.5 Billion R&D Hub in Beijing, Expanding Vaccine and Biotech Partnerships
By Thomas Yuan

BEIJING — AstraZeneca has unveiled a sweeping $2.5 billion investment plan to build its sixth global strategic research and development center in Beijing, a move that underscores the pharmaceutical giant’s long-term commitment to China’s life sciences sector and its ambitions in biopharmaceutical innovation.

The new facility will serve as a cornerstone for AstraZeneca’s expansion in China, with the company also announcing several high-profile partnerships aimed at advancing next-generation drug development and vaccine production.

Among the newly signed agreements, AstraZeneca has entered into R&D cooperation with Hebo Pharmaceuticals to pursue multi-specific antibody therapies, as well as a development collaboration with Yuansisheng Peptide focused on macrocyclic peptide drugs, a cutting-edge category of targeted therapies.

In addition, the company has launched a joint venture with Kangtai Biological, which will focus on the development, production, and commercialization of innovative vaccines for respiratory diseases and other infectious conditions. This will be AstraZeneca’s first and only vaccine production base in China, marking a significant milestone in the company’s localized pharmaceutical strategy.

As a result of these investments and collaborations, AstraZeneca anticipates expanding its Beijing workforce to 1,700 employees, reinforcing the capital city’s role as a critical hub in the company’s global medical technology and health product development network.

The announcement comes as multinational pharmaceutical firms continue to deepen their presence in China’s rapidly evolving healthcare landscape, where demand for advanced medical supply systems, innovative therapies, and public health infrastructure remains strong and growing.

https://finance.eastmoney.com/a/202503233353304945.html